Parnassus Investments LLC Has $52.72 Million Holdings in Repligen Co. (NASDAQ:RGEN)

Parnassus Investments LLC lowered its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 366,232 shares of the biotechnology company's stock after selling 15,239 shares during the period. Parnassus Investments LLC owned 0.65% of Repligen worth $52,715,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Resources Management Corp CT ADV bought a new position in Repligen during the 3rd quarter worth $37,000. Quarry LP grew its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. increased its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the period. Global Retirement Partners LLC raised its stake in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 90 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RGEN. HC Wainwright reiterated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group raised their price target on Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday. They set an "in-line" rating and a $155.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Finally, StockNews.com lowered shares of Repligen from a "hold" rating to a "sell" rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $178.64.

Remove Ads

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.20% of the company's stock.

Repligen Price Performance

Shares of NASDAQ RGEN traded down $8.47 during mid-day trading on Tuesday, hitting $144.34. 1,160,859 shares of the stock traded hands, compared to its average volume of 646,141. The company has a market cap of $8.09 billion, a PE ratio of -283.02, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $200.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50 day simple moving average of $157.16 and a two-hundred day simple moving average of $148.53.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. As a group, equities research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.